|
|
Article: NeoPharm To Announce IL13-PE38 Phase I/II Data for Malignant Glioma At Society for Neuro-Oncology - SNO - Meeting Tomorrow.
- Article from:
- Business Wire
- Article date:
- November 15, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors
LAKE FOREST, Ill.--(BUSINESS WIRE)--Nov. 15, 2001
Three abstracts to be presented at SNO conference expected
to reveal new findings on potential treatment for a rare and deadly
brain cancer for which there is no known cure
NeoPharm, Inc. (Nasdaq National Market: NEOL) announced that on November 16, Phase I/II safety and efficacy studies on IL13-PE38 will be presented for the first time in a scientific forum at the Sixth Annual Meeting of the World Federation of Neuro-Oncology/ Society for Neuro-Oncology (SNO) in Washington, D.C. Three abstracts are expected to reveal preliminary findings which suggest that the ...